Evidence map›Paper›PMID 40613080›Full record

ArticleToxicology reports2025

Transgenerational toxicity of Aroclor 1232 by inhalational route in mouse model.

Sivaselvakumar Muthusamy, Ramanujam Narayanan

Abstract read
In one paragraph

Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sivaselvakumar MuthusamyPSG-Center for Molecular Medicine & Therapeutics (PSG-CMMT), PSG Institute of Medical Sciences & Research, Coimbatore, India.
Ramanujam NarayananPharmacology, PSG Institute of Medical Sciences & Research, Coimbatore, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Aroclor 1232 is a commercial mixture of polychlorinated biphenyls with inhalational toxicological implications as it contains semi-volatile congeners like PCB 77, along with highly lipophillic ones like PCB 180. We aimed to assess the trans-generational behavioral toxicities of this complex mixture in mice by inhalational dosing chamber. We also aimed to evaluate the penetrability of PCBs across placental and lactational routes in mice in this study. Methods: We assessed the probable route of penetration in the first generation of litters using behavioral scores as surrogate markers of developmental toxicity. We also quantified plasma concentrations of key PCBs and anthropometric parameters for trans-generational comparability. Results: PCBs are responsible for behavioral toxicities across one generation of mice by hazardous exposures via the inhalational route. Behavioral scores of F1 and F2generation mice indicated as surrogate endpoints that PCBs are concentrated in lactating milk more than placental route in the next generation of mice. No significant lethality or effects on anthropometrical parameters were detected across one generation although the congeners were detected in plasma of the litters when they were 12-14 weeks age. Conclusion: PCBs may pose both indoor and outdoor volatile hazard by inhalational routes and cause behavioral deficits across one generation by transfer via lactational routes. PCB 77 is more evident of penetrating trans-generationally and produces behavioral toxicities in subsequent generations. They definitely carry inhalational hazard in workplaces and outdoor as environmental pollutants and neuroendocrine disruptors.

Indexed as

Developmental toxicityInhalational toxicityPolychlorinated Biphenyl (PCB)Trans-generational toxicityVolatile hazard assessment

Identifiers

PMID40613080
PMCPMC12214260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.